ID

16696

Description

Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc (OSI Pharmaceuticals) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of Study: Adverse Events

Lien

https://clinicaltrials.gov/ct2/show/NCT00373425

Mots-clés

Versions (1)
  1. 01/08/2016 01/08/2016 -
Téléchargé le

1 août 2016

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Adverse Events, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425

Anglais

Adverse Events, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

1 Formulaires  
Adverse Events
Description

Adverse Events

Did any Adverse Events occur?
Description

Adverse Events

Type de données

boolean

Alias
UMLS CUI [1]
C0877248
Long-Term Follow-Up Adverse Events
Description

Long-Term Follow-Up Adverse Events

Sign/Symptom or Adverse Event
Description

Record ALL Baseline Signs and Symptoms that occur within 24 hours prior to First Dosing. ALL Adverse Events, including Serious Adverse Events should be recorded. In addition, ALL Serious Adverse Events must be recorded on the Serious Adverse Event Report Form.

Type de données

text

Alias
UMLS CUI [1]
C0877248
Severity (CTC Grade)
Description

Grade severity (1,2,3,4,5) using NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0. A change in CTC grade should be recorded as a separate event.

Type de données

integer

Alias
UMLS CUI [1]
C1710066
Start Date: pretreatment
Description

Adverse Event Start Date

Type de données

boolean

Alias
UMLS CUI [1]
C2697888
Start Date
Description

If not pretreatment, please specify start date

Type de données

date

Alias
UMLS CUI [1]
C2697888
Stop Date: continuing
Description

Adverse Event End Date

Type de données

boolean

Alias
UMLS CUI [1]
C2697886
Stop Date
Description

If not continuing, please specify stop date

Type de données

date

Alias
UMLS CUI [1]
C2697886
Serious
Description

If event is serious, complete the SERIOUS ADVERSE EVENT FORM and fax to the appropriate number on the CRF General lnstructions page.

Type de données

boolean

Alias
UMLS CUI [1]
C1710056
Related to study treatment
Description

A change in relationship should be recorded as a separate event.

Type de données

boolean

Alias
UMLS CUI [1]
C1510821
Action taken
Description

If event caused drug discontinuation, complete the Withdrawal From Study Due To Nonserious Adverse Event Form and fax to the appropriate number on the CRF General lnstructions page.

Type de données

integer

Alias
UMLS CUI [1]
C2826626
Retour au début de la page

Similar models

Adverse Events, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
Adverse Events
Adverse Events
Item
Did any Adverse Events occur?
boolean
C0877248 (UMLS CUI [1])
Item Group
Long-Term Follow-Up Adverse Events
Adverse Events
Item
Sign/Symptom or Adverse Event
text
C0877248 (UMLS CUI [1])
Item
Severity (CTC Grade)
integer
C1710066 (UMLS CUI [1])
Adverse Event Severity
Code List
Severity (CTC Grade)
CL Item
1 (1)
CL Item
2 (2)
CL Item
3 (3)
CL Item
4 (4)
CL Item
5 (5)
Adverse Event Start Date
Item
Start Date: pretreatment
boolean
C2697888 (UMLS CUI [1])
Adverse Event Start Date
Item
Start Date
date
C2697888 (UMLS CUI [1])
Adverse Event End Date
Item
Stop Date: continuing
boolean
C2697886 (UMLS CUI [1])
Adverse Event End Date
Item
Stop Date
date
C2697886 (UMLS CUI [1])
Seriousness of Adverse Event
Item
Serious
boolean
C1710056 (UMLS CUI [1])
Relation to study treatment
Item
Related to study treatment
boolean
C1510821 (UMLS CUI [1])
Item
Action taken
integer
C2826626 (UMLS CUI [1])
Action Taken
Code List
Action taken
CL Item
None (1)
CL Item
Dose Reduced (2)
CL Item
Dose Temporarily Withheld (3)
CL Item
Dose Temporarily Withheld and Reduced (4)
CL Item
Drug Discontinued (5)
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial